Cancer cells expressing high Bcl-2 levels are sensitive to ABT-737 treatment [2,5,6], and ABT-737 combines with cytotoxic drugs against solid tumors and hematological malignancy and overcome cancer cell resistance [5,6,7,8,9,10]. Here, BCL2 is linked to cancer.